Mankind Pharma forays into agri-tech space, plans to invest Rs 200 crore

Mankind Pharma on Monday announced its foray into the agri-tech segment, with plans to invest up to Rs 200 crore in the first two to three years

Mankind Pharma
Press Trust of India New Delhi
2 min read Last Updated : Apr 05 2022 | 12:57 AM IST

Mankind Pharma on Monday announced its foray into the agri-tech segment, with plans to invest up to Rs 200 crore in the first two to three years.

The company has set up a new arm Mankind Agritech Pvt Ltd, which will offer a variety of crop care solutions to Indian farmers, including weedicides, insecticides, fungicides, plant growth regulators and biologicals, Mankind Pharma said in a statement.

"We are happy to announce our launch in the agritech domain with long-term investment plans, with an initial (Rs) 150 to (Rs) 200 crore capex infusion in the first two to three years," Mankind Pharma Managing Director and Vice-Chairman Rajeev Juneja said.

Asserting that technology is playing a crucial role in ensuring the growth of the agriculture sector in India, he said, "Agritech has the potential to scale up the agricultural industry through technological intervention. If the farmers get the right products and tools they would be in a position to make an informed decision of using input and right technology".

The new vertical will be headed by Indian agrochemical industry veteran Partha Sengupta, who was the national marketing head and part of the senior leadership team at Dhanuka Agritech Ltd, overseeing marketing operations in India, Bangladesh and Nepal, the company said.

The decision behind foraying into this division is to assist Indian farmers by providing new-age technologies and helping farmers for the betterment of the rural sector, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Mankind PharmaHealth Medical Pharmapharmaceutical firms

First Published: Apr 05 2022 | 12:57 AM IST

Next Story